Media coverage about USANA Health Sciences (NYSE:USNA) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. USANA Health Sciences earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.835705742626 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of USANA Health Sciences (USNA) opened at $70.55 on Tuesday. USANA Health Sciences has a one year low of $52.55 and a one year high of $72.80. The firm has a market cap of $1,701.07, a PE ratio of 18.76 and a beta of 1.08.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.11. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.38%. The company had revenue of $261.77 million during the quarter, compared to analyst estimates of $259.52 million. During the same period in the prior year, the firm earned $2.40 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. analysts predict that USANA Health Sciences will post 3.7 EPS for the current fiscal year.

A number of analysts have recently issued reports on USNA shares. Pivotal Research boosted their target price on shares of USANA Health Sciences from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, October 25th. BidaskClub raised shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th.

In other USANA Health Sciences news, Director Myron W. Wentz sold 164,916 shares of the stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $66.40, for a total transaction of $10,950,422.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Global Ltd Gull sold 79,294 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $57.61, for a total transaction of $4,568,127.34. Following the sale, the insider now directly owns 12,272,013 shares of the company’s stock, valued at $706,990,668.93. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 806,060 shares of company stock valued at $51,895,822. 53.20% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect USANA Health Sciences (USNA) Stock Price” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at

About USANA Health Sciences

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with's FREE daily email newsletter.